Antibiotic Resistance Markets, 2023

Dublin, April 12, 2018 -- The "Antibiotic Resistance Markets - Pharmaceutical Therapeutics - By Pathogen and Therapy Type Strategies & Trends 2018 to 2023" report has been added to ResearchAndMarkets.com's offering.

Antimicrobial Resistance is creating new kinds of infections and superbugs that are resistant to current antibiotic medicines. New drugs and technologies are under development to stop these superbugs. These pharmaceutical technologies have the potential to displace existing antibiotics. We have identified the 6 Key Large Opportunities in this space and developed market forecasts.

The report has looked at the technology picture too, giving you, plain language understanding of the different ways pathogens, and infections, can be treated. This is a market with a lot of players, there are over 100 biotechnology companies profiled in the report. Understand this unfolding market opportunity and the players in it.

All report data is available in Excel format on request.

Make investment decisions and valuations with confidence using the latest data.

Key Topics Covered:

1. Introduction and Market Definition
1.1 The Growing Threat and Opportunity of Antimicrobial Resistance
1.2 Defining the Opportunity
1.2.1 Revenue Market Size
1.3 Methods and Sources
1.4 U.S. Antibiotic Markets - Perspective
1.4.1 U.S. Outpatient Use of Antibiotics
1.4.2 U.S. Pharmaceutical Spending

2. Overview of a Dynamic Market
2.1 Market Players - Roles & Impacts
2.1.1 Drug manufacturers - Larger/pharmaceutical
2.1.2 Drug manufacturers - Generic
2.1.3 Contract Research and Manufacturing
2.1.4 In Vitro Diagnostics Industry
2.1.5 Drug Marketing Companies
2.1.6 Biotechnology Companies
2.1.7 Regulatory Bodies
2.2 Understanding Antimicrobial Resistance
2.2.1 What is Antimicrobial Resistance (AMR)
2.2.2 Bacteria and Other Microbes
2.2.3 The History of Antibiotics
2.2.4 The Role of Animal Husbandry
2.2.5 The Implications of Horizontal Transfer
2.2.6 The Threat of AMR
2.3 The Changing Road to New Antibiotics & Technologies
2.4 The Key Role of Diagnostics in AMR

3. The Market Opportunity of AMR
3.1 The Key Large Market Opportunities in AMR
3.1.1 Streptococcus Pneumoniae (DRSP)
3.1.2 Campylobacter (DRC)
3.1.3 Clostridium Difficile (CD)
3.1.4 Staphylococcus aureus (MRSA)
3.1.5 Neisseria gonorrhoeae (DRNG)
3.1.6 Salmonella (DRNTS)
3.2 Therapeutic Technology Development Opportunities
3.2.1 Using Viruses Against Bacteria
3.2.2 Hydrolytic Enzymes Join the Fight.
3.2.3 Antibodies.
3.2.4 Vaccines
3.2.5 Probiotic Technology
3.2.6 Peptides vs. Pathogens
3.2.7 Mining Obsolete Science
3.2.8 CRISPR Antibiotics
3.3. Antibiotic Resistance Recent Developments
3.3.1 Recent Developments - Importance and How to Use This Section
3.3.2 Importance of These Developments
3.3.3 How to Use This Section
3.3.4 Superbug Arises in China
3.3.5 Bruker Announces Acquisition of MERLIN
3.3.6 Antibiotics Firms Cempra, Melinta Therapeutics Agree to Merger
3.3.7 Antibiotic Alternative Micreos wins Most Impactful Innovation
3.3.8 Roche kicks antibiotic development into Warp Drive
3.3.9 Iterum Gains Support for Sulopenem Development
3.3.10 VenatoRx Pharmaceuticals Raises $42 Million Series B
3.3.11 Wockhardt Receives Approval for Phase III Trial
3.3.12 Phagelux, Inc. Announces Collaboration with Johnson & Johnson
3.3.13 bioMrieux, Inc. and McKesson Medical-Surgical Announce Distribution Alliance
3.3.14 AstraZeneca to sell antibiotics branch to Pfizer
3.3.15 Microbiotix and AMR Centre Announce Co-Development Agreement
3.3.16 Hennepin Life Sciences Presents Pre-Clinical Data
3.3.17 bioMrieux receives FDA clearance for expanded pathogen identification capability
3.3.18 Sequoia Sciences Receives FDA Fast Track Designation
3.3.19 Forge Therapeutics Presents New Efficacy Data
3.3.20 Acquisition Strategy Fills Out Roche's Pipeline
3.3.21 Alopexx completes trial of broad-spectrum anti-microbial vaccine
3.3.22 Integrated Biotherapeutics Partners with CARB-X for MRSA Vaccine
3.3.23 BD Molecular Test for Infectious Diarrhea Cleared
3.3.24 Fusion Genomics Developing All Pathogens Diagnostic.

4. Key Biotechnology Companies and Their Technology
4.2 Therapeutics
4.2.1 The Medicines Company
4.2.2 Melinta Therapeutics
4.2.3 Arsanis
4.2.4 Phage Technologies S.A
4.2.5 Westway Health
4.2.6 Tetraphase Pharmaceuticals
4.2.7 BioVersys GmbH
4.2.8 Nabriva Therapeutics.
4.2.9 Macrolide Pharmaceuticals
4.2.10 Nemesis Bioscience
4.2.11 C3J Therapeutics, Inc.
4.2.12 EpiBiome
4.2.13 discuva
4.2.14 SmartPhage
4.2.15 AmpliPhi Biosciences
4.2.16 Pherecydes Pharma
4.2.17 Micreos
4.2.18 Procarta Biosystems
4.2.19 Lumavita
4.2.20 Madam Therapeutics
4.2.21 Priaxon
4.2.22 Biolytx Pharmaceuticals
4.2.23 AntibioTx
4.2.24 Xellia Pharmaceuticals
4.2.25 Paratek Pharmaceuticals
4.2.26 Synereca Pharmaceuticals
4.2.27 Allecra Therapeutics
4.2.28 Fixed Phage
4.2.29 Enanta Pharmaceuticals, Inc.
4.2.30 Demuris
4.2.31 Prommune
4.2.32 Biosergen
4.2.33 Innovation Pharmaceuticals
4.2.34 Aviragen Therapeutics
4.2.35 Achillion Pharmaceuticals
4.2.36 ImmunNovative Developments, S.L.
4.2.37 Achaogen, Inc.
4.2.38 SelectX Pharmaceuticals, Inc.
4.2.39 TaiGen Biotechnology Co., Ltd.
4.2.40 Theravance Biopharma
4.2.41 Abbvie
4.2.42 KYORIN Pharmaceutical Co.,Ltd.
4.2.43 Iterum Therapeutics Limited
4.2.44 Forge Therapeutics
4.2.45 Alopexx Vaccine LLC
4.2.46 Integrated Biotherapeutics
4.2.47 Hennepin Life Sciences
4.2.48 Fedora Pharmaceuticals Inc.
4.2.49 Contrafect Corporation
4.2.50 Basilea Pharmaceutica Ltd.
4.2.51 AiCuris
4.2.52 RedHill Biopharma
4.2.53 Redx Pharma Plc/ Redx Anti Infectives Ltd.
4.2.54 ABAC Therapeutics
4.2.55 Alaxia SAS
4.2.56 Antabio S.A.S
4.2.57 Auspherix Ltd
4.2.58 BioFilm Pharma
4.2.59 Centauri Therapeutics Ltd
4.2.60 Combioxin SA
4.2.61 Da Volterra
4.2.62 Debiopharm International SA
4.2.63 Deinobiotics/Deinove
4.2.64 Destiny Pharma plc
4.2.65 Eligo Bioscience
4.2.66 Helperby Therapeutics Ltd
4.2.67 Karveel Pharmaceuticals
4.2.68 MaaT Pharma
4.2.69 Motif BioSciences, Inc / Motif Bio PLC
4.2.70 Mutabilis SAS
4.2.71 Neem Biotech Ltd
4.2.72 Northern Antibiotics Oy (Ltd)
4.2.73 Nosopharm
4.2.74 NovaBiotics Ltd
4.2.75 Phico Therapeutics Ltd
4.2.76 Polyphor Ltd
4.2.77 QureTech Bio AB
4.2.78 SetLance srl
4.2.79 Ultupharma AB
4.2.80 Vaxdyn
4.2.81 Vibiosphen
4.2.82 Bioaster
4.2.83 Vivexia
4.2.85 KBP Biosciences
4.2.86 Absynth Biologics
4.2.87 Spero Therapeutics
4.2.88 Merck
4.2.89 Symphogen
4.2.90 Warp Drive Bio
4.2.91 Johnson & Johnson (Janssen)
4.2.92 Pfizer
4.2.93 Allergan
4.2.95 Novartis
4.2.97 AstraZeneca
4.2.100 Cipla
4.2.101 DSM Sinochem Pharmaceuticals
4.2.102 Wockhardt Ltd.
4.2.103 VenatoRx Pharmaceuticals
4.2.104 MicuRx
4.2.105 Entasis Therapeutics
4.2.106 Merlion Pharmaceuticals
4.3 The Therapeutics Race - Summary of Companies Research Areas

5. Country Market Sizes - North America 2017 to 2023

6. Country Markets - Europe 2017 to 2023

7. Country Markets - Asia Pacific 2017 to 2023

8. Country Markets - Latin America, Africa & The Middle East 2017 to 2023

9. Global Market Summary 2017 to 2023

10. The Future of AMR

Appendices
I. United States Medicare System: Top Selling Drugs 2011-2015

For more information about this report visit https://www.researchandmarkets.com/research/lmd4r7/antibiotic?w=12

CONTACT: ResearchAndMarkets.com
         Laura Wood, Senior Manager
         [email protected]
         For E.S.T Office Hours Call 1-917-300-0470
         For U.S./CAN Toll Free Call 1-800-526-8630
         For GMT Office Hours Call +353-1-416-8900
         Related Topics: Antibiotics